M (@RiskInhibitor) header
M (@RiskInhibitor) profile picture

I like science, I like money. L/S Don't overthink it, that's my job. NFA

Arklay Laboratory
Joined June 2019
Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)Photo by M (@RiskInhibitor)
it's a research business first and foremost.
1
9
6,816
$ZURA I am in need of post hoc analysis, if you have thoughts, please share. I don’t have the time to do it myself right now.
2
6
1,291
so much happening this month im too busy
1
4
617
M retweeted
Larry Ellison on conviction
45
192
20
2,450
139,212
Pugna mecum
1
1
7
2,064
$ARTV gone now $IMVT has d2t RR market currently uncontested. Do some simple risk adj npv math on just that indication and tell me current market cap is anything close to sound
4
1
14
3,351
People finally realized that it's the payload and linker chemistry that drives the efficacy & durability of ADC.
6
2
2
58
10,517
I met this guy recently who does coke everyday and hes still obese. Imagine that. Sit and think about it for a while. If that doesn't inspire you to be great idk.
1
12
1,089
$IMVT at 28 is a once in a year opportunity
3
1
14
2,324
just turned $1k to $9
277
5,372
179
112,989
2,013,447
$IRON Hit. Much to think about
4
9
3,291
Why is everyone’s substack paid I think I should make mine paid am I doing something wrong?
2
14
1,559
Send tickers
13
5
1,720
So many easy shorts Q4 26 & Q1 27
3
1
8
1,846
I gotta say, there's a lot of people coming out and saying that MoAs are often unknown but this really isn't true. Yes there are exceptions to the rule, but the overwhelmingly majority of drugs MoAs are known. ADCs kill cells with payloads. TCEs leverage t cell killing. Even naked mAbs are exquisitely well described with canonical antibody medicated cell killing and even extra mechanisms like enzyme blocking. Literally all of rational drug design is predicated on knowing the MoA and designing an agent around it. I do respect the notion of leveraging poly pharmacology, I did write a 30pg report and do an hour long video on a polyclonal antibody product. But even then it's an exception. Probably over 3/4 of drug programs in dev are just copy cat me toos. I think we may see slightly more drug dev in a poly pharmacological framework, but this is not going to start taking off for like a dozen very practical reasons in drug dev and if it did it would overhwlmingly end in failure and kill programs/ companies
The reaction to Terence Tao’s cancer thought experiment is revealing. Even brilliant people have a different mental model of how medicine works than those of us inside it. Drugs can deliver benefits beyond anything we anticipated (GLP-1s, anti-PD1), or fall far short of compelling mechanistic rationales. Clinical evidence is probabilistic and mechanistic understanding is incomplete. We undermine trust when we pretend otherwise. @VPrasadMDMPH @anish_koka @venkmurthy @adamcifu
6
4
3
36
10,414
Very short $IRON
2
22
3,520
the "weekend" is propaganda to keep you poor
2
2
18
1,286
If we had a woman president would period tracking be valid macro analysis or n?
6
18
1,407
I forgot about this tweet lmao just for the record this did not happen
After $GOSS short I will be full port $AVBP through readout
2
27
1,895
the $IRON drug is worse than you think
18
1,600
If a man is not deeply hostile towards your weak behaviour he is not your friend and you should never trust him
12
149
5
1,699
43,410